NCT05883072 is a clinical trial of Exploring AI-Chatbot in Diabetes Mellitus, Type 2, sponsored by Pakistan Council of Scientific and Industrial Research.

Who is sponsoring NCT05883072?

NCT05883072 is sponsored by Pakistan Council of Scientific and Industrial Research.

What drugs are being tested in NCT05883072?

Interventions in NCT05883072: Exploring AI-Chatbot.

What condition does NCT05883072 study?

NCT05883072 studies Diabetes Mellitus, Type 2, Diabetic Retinopathy, Diabetes.

Is NCT05883072 still recruiting?

NCT05883072 is currently recruiting now. Last updated 5 June 2023.

Last reviewed 2023-06-05 · How we verify

NCT05883072

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exploring the Effectiveness of AI Generative Models for Diabetic Patients

Recruiting now Last updated 5 June 2023

What this trial tests

trial testing Exploring AI-Chatbot in Diabetes Mellitus, Type 2 in 300 participants. Currently enrolling.

Timeline

5 January 2023

Primary endpoint
30 December 2024

31 December 2026

Quick facts

Lead sponsor	Pakistan Council of Scientific and Industrial Research
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	300
Start date	5 January 2023
Primary completion	30 December 2024
Estimated completion	31 December 2026
Sites	1 location across Pakistan

Drugs / interventions tested

Exploring AI-Chatbot

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
Diabetes — all drugs for Diabetes →

Sponsor

Pakistan Council of Scientific and Industrial Research

Who can join

Adults 18 to 100, any sex, with Diabetes Mellitus, Type 2 or Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We plan to explore the usability of Generative AI-Chatbot for Diabetic Patient

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Pakistan Council of Scientific and Industrial Research trials

Trials by the same sponsor.

NCT06287645 — Color Fundus Photograph With Experts Labelling · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05883072 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pakistan Council of Scientific and Industrial Research
Last refreshed: 5 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05883072.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing